Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for Vascular Inflammation in Psoriasis
NCT01722214Phase 4Completed
- Sponsor
- Innovaderm Research
- Start
- Nov 2012
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in plaque psoriasis comparing Group Adalimumab with Placebo Group (2 arms). Primary endpoint: Target to Background Ratio of the Ascending Aorta at Week 16. Started Nov 2012; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01722214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01722214.